CK Life Sciences Int'l., (Holdings) Inc. (HKG:0775)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.7500
0.00 (0.00%)
May 7, 2026, 4:08 PM HKT
Market Cap7.21B +56.3%
Revenue (ttm)5.41B -2.0%
Net Income-186.81M
EPS-0.02
Shares Out9.61B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,068,000
Average Volume1,896,304
Open0.7200
Previous Close0.7500
Day's Range0.7200 - 0.7500
52-Week Range0.6400 - 1.0800
Beta0.40
RSI55.24
Earnings DateMay 12, 2026

About HKG:0775

CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 1,920
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 0775
Full Company Profile

Financial Performance

In 2025, HKG:0775's revenue was 5.41 billion, a decrease of -2.04% compared to the previous year's 5.52 billion. Losses were -186.81 million, 47.6% more than in 2024.

Financial Statements

News

Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline

CK Life Sciences, a unit of Li Ka-shing-backed CK Group, plans to bring its cancer vaccine candidates to mainland China through a “fast track” channel as Beijing moves to accelerate early-stage drug d...

5 weeks ago - South China Morning Post

CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs

CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech...

7 months ago - South China Morning Post

TransCode Acquires Polynoma From CK Life Sciences

(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candi...

7 months ago - Nasdaq

CK Life’s new CEO counts on Big Pharma experience to boost new drug success, earnings

Lance Yuen spent two decades at Bristol-Myers Squibb and Bayer in the region before becoming the CEO at CK Life Sciences last month.

1 year ago - South China Morning Post